Molecular determinants of epistasis in HIV-1 protease: Elucidating the interdependence of L89V and L90M mutations in resistance

Protease inhibitors have the highest potency among antiviral therapies against HIV-1 infections, yet the virus can evolve resistance. Darunavir (DRV), currently the most potent FDA approved protease inhibitor, retains potency against single site mutations. However, complex combinations of mutations...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochemistry
Hauptverfasser: Henes, Mina, Kosovrasti, Klajdi, Lockbaum, Gordon J., Leidner, Florian, Nachum, Gily S., Nalivaika, Ellen A., Bolon, Daniel N.A., Yilmaz, Nese Kurt, Schiffer, Celia A., Whitfield, Troy W.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6941756/
https://ncbi.nlm.nih.gov/pubmed/31386353
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.biochem.9b00446
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge